HDAC4 (Ab-632) Antibody

What is HDAC4 and why is the Ab-632 region significant for antibody development?

HDAC4 (Histone deacetylase 4) is responsible for the deacetylation of lysine residues on the N-terminal part of core histones (H2A, H2B, H3, and H4). This deacetylation creates an epigenetic repression tag that plays crucial roles in transcriptional regulation, cell cycle progression, and developmental events . HDAC4 functions through the formation of large multiprotein complexes and is involved in muscle maturation through interactions with myocyte enhancer factors including MEF2A, MEF2C, and MEF2D .

The Ab-632 region corresponds to a peptide sequence around amino acids 630-634 (A-Q-S-S-P) derived from human HDAC4 . This region is particularly significant because it contains the Serine 632 residue, which is a critical phosphorylation site that regulates HDAC4's subcellular localization and function. When phosphorylated at Ser632, HDAC4 tends to localize to the cytoplasm; when dephosphorylated, it accumulates in the nucleus where it can regulate gene expression . This phosphorylation-dependent shuttling mechanism makes antibodies targeting this region valuable tools for studying HDAC4 regulation in various cellular contexts.

How does phosphorylation at Ser632 affect HDAC4 function and subcellular localization?

Phosphorylation at Ser632 of HDAC4 serves as a crucial regulatory mechanism that determines its subcellular localization and subsequent function. When HDAC4 is phosphorylated at Ser632, it binds to 14-3-3 proteins, which facilitate its export from the nucleus to the cytoplasm . This cytoplasmic sequestration prevents HDAC4 from interacting with nuclear transcription factors and chromatin, effectively inhibiting its gene-repressive functions.

Research has demonstrated that in wild-type cells, most HDAC4 is phosphorylated and predominantly cytoplasmic . Specifically, in western blot analyses of cell and tissue extracts, phosphorylated HDAC4 exhibits a characteristic slower migration pattern (appearing as a higher molecular weight band) compared to the unphosphorylated form .

The phosphorylation state of HDAC4 is dynamically regulated by various kinases and phosphatases. Calcium/calmodulin-dependent protein kinase (CaMK) has been identified as one of the primary kinases that phosphorylate HDAC4 at Ser632 . Protein kinase A (PKA) activation also appears to be involved in regulating HDAC4 phosphorylation and nuclear import in response to certain stimuli like parathyroid hormone (PTH) . Conversely, protein phosphatase 2A (PP2A) can dephosphorylate HDAC4, promoting its nuclear accumulation .

What are the optimal protocols for using HDAC4 (Ab-632) Antibody in Western blotting applications?

For optimal Western blotting results with HDAC4 (Ab-632) Antibody, researchers should follow this methodological approach:

Sample preparation:

• Extract proteins from cells or tissues using RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, and protease inhibitors)

• For nuclear vs. cytoplasmic analysis, use nuclear and cytoplasmic extraction reagents (e.g., NE-PER from Thermo Scientific)

• Determine protein concentration using Bradford or similar assay

• For phosphorylation studies, include phosphatase inhibitors in all buffers

Western blotting protocol:

• Recommended dilution: 1:500-1:1000

• Predicted molecular weight: 140 kDa

• Run samples on 7-8% SDS-PAGE for optimal resolution of phosphorylated vs. non-phosphorylated forms

• Transfer to PVDF membrane (recommended over nitrocellulose for phospho-proteins)

• Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Incubate with HDAC4 (Ab-632) Antibody overnight at 4°C

• Wash 3× with TBST

• Incubate with appropriate secondary antibody (typically anti-rabbit HRP at 1:5000-1:10000)

• Develop using enhanced chemiluminescence

Validation controls:

• Include phosphatase treatment controls (e.g., incubate nuclear extracts with calf intestinal alkaline phosphatase) to confirm phosphorylation-dependent bands

• Use positive control samples (e.g., HepG2 cell extracts)

• For phospho-specific antibodies, include both phosphorylated and non-phosphorylated samples

This protocol enables researchers to clearly distinguish between phosphorylated and non-phosphorylated forms of HDAC4, which typically appear as distinct bands with different migration patterns on SDS-PAGE.

How can HDAC4 (Ab-632) Antibody be effectively used in immunofluorescence studies?

For successful immunofluorescence applications with HDAC4 (Ab-632) Antibody, researchers should implement the following protocol:

Sample preparation:

• Grow cells on glass coverslips or prepare tissue sections (10-20 μm thickness recommended)

• Fix cells using one of these methods:

  • 4% paraformaldehyde (10 minutes at room temperature) for preserving cell architecture

  • Methanol fixation (10 minutes at -20°C) for better epitope accessibility

• Permeabilize with 0.1-0.5% Triton X-100 in PBS (5 minutes) if using paraformaldehyde fixation

Immunofluorescence protocol:

• Block with 5% normal serum (from the species of secondary antibody) in PBS with 0.1% Triton X-100 for 1 hour

• Dilute HDAC4 (Ab-632) Antibody 1:100-1:200 in blocking buffer

• Incubate overnight at 4°C in a humidified chamber

• Wash 3× with PBS (5 minutes each)

• Apply fluorophore-conjugated secondary antibody (e.g., Goat Anti-Rabbit IgG with FITC)

• Counterstain nuclei with DAPI or Hoechst (1 μg/mL, 5 minutes)

• Wash 3× with PBS

• Mount with anti-fade mounting medium

Advanced techniques for subcellular localization:

• Co-staining with nuclear (e.g., DAPI) and cytoplasmic markers

• For nuclear-cytoplasmic shuttling studies, combine with treatments that affect HDAC4 localization:

  • ATM inhibitors (caffeine 2 mM or KU55933 10 μM)

  • Phosphatase inhibitors (e.g., endothall)

  • PKA activators or inhibitors (e.g., H89)

Image acquisition considerations:

• Use confocal microscopy for precise subcellular localization

• Capture z-stacks to ensure complete visualization of nuclear vs. cytoplasmic distribution

• Employ consistent exposure settings across experimental conditions

• For quantitative analysis, collect images from multiple fields (>10) and perform unbiased analysis of nuclear vs. cytoplasmic signal intensity ratios

This approach will allow researchers to clearly visualize HDAC4 subcellular distribution patterns, which is particularly important when studying conditions that affect its nuclear-cytoplasmic shuttling, such as ATM deficiency or specific kinase/phosphatase activities.

How should researchers interpret changes in HDAC4 subcellular localization in ATM-deficient models?

When analyzing HDAC4 subcellular localization in ATM-deficient models, researchers should consider the following interpretational framework:

Normal localization pattern:
In wild-type cells and tissues, HDAC4 predominantly localizes to the cytoplasm of neurons, particularly Purkinje cells . This cytoplasmic localization is maintained by phosphorylation at Ser632, which promotes binding to 14-3-3 proteins and cytoplasmic retention .

Changes in ATM-deficient models:

• In ATM-deficient models (both human A-T cerebella and Atm−/− mouse tissues), HDAC4 shows strong nuclear accumulation, particularly in Purkinje cells

• This nuclear accumulation is specific to HDAC4; related proteins HDAC5 and HDAC9 do not show similar translocation

• The nuclear HDAC4 in ATM-deficient tissues is predominantly in the unphosphorylated state

Mechanistic interpretation:
The nuclear accumulation of HDAC4 in ATM-deficient models can be interpreted through the following molecular mechanism:

• ATM normally phosphorylates the PP2A-A subunit at S401

• This phosphorylation prevents PP2A from associating with HDAC4

• In ATM deficiency, unphosphorylated PP2A-A associates with HDAC4 and dephosphorylates it at Ser632

• Dephosphorylated HDAC4 dissociates from 14-3-3 proteins and translocates to the nucleus

• Nuclear HDAC4 binds to chromatin and transcription factors (MEF2A and CREB), leading to histone deacetylation and altered gene expression

Functional consequences:
The nuclear accumulation of HDAC4 in ATM-deficient neurons has significant functional consequences:

• Altered neuronal gene expression profiles

• Increased neuronal sensitivity to DNA damage

• Contribution to neurodegenerative changes observed in ataxia telangiectasia

When interpreting experimental data, researchers should consider both the subcellular distribution pattern (using immunofluorescence) and the phosphorylation state (using Western blotting with phospho-specific antibodies) of HDAC4. Changes in these parameters can provide insights into the underlying pathological mechanisms in ATM-deficient models and potential therapeutic targets.

What are the distinguishing features between phospho-Ser632 specific and total HDAC4 (Ab-632) antibodies in research applications?

Understanding the distinctions between phospho-Ser632 specific and total HDAC4 (Ab-632) antibodies is crucial for selecting the appropriate reagent and interpreting experimental results:

Phospho-Ser632 HDAC4 antibodies:

• Epitope recognition: These antibodies specifically detect HDAC4 only when phosphorylated at Ser632, typically recognizing the peptide sequence around phosphorylation site A-Q-S(p)-S-P

• Production method: Generated by immunizing with synthetic phosphopeptide and purified using affinity chromatography with phospho-epitope specific peptides; non-phospho specific antibodies are removed during purification

• Research applications: Ideal for:

  • Monitoring kinase/phosphatase activity affecting HDAC4

  • Studying conditions that alter HDAC4 phosphorylation status

  • Assessing 14-3-3 protein binding potential

• Signal interpretation: Signal intensity directly correlates with phosphorylation levels at Ser632

• Pattern in Western blots: Typically detects only the slower migrating band (~140 kDa) in wild-type samples

Total HDAC4 (Ab-632) antibodies:

• Epitope recognition: Detect HDAC4 protein around the 632 region regardless of phosphorylation status, typically recognizing the peptide sequence A-Q-S-S-P

• Production method: Generated using synthetic peptide (unphosphorylated) and purified by affinity chromatography

• Research applications: Ideal for:

  • Measuring total HDAC4 protein levels

  • Determining subcellular localization

  • Immunoprecipitation experiments

• Signal interpretation: Signal intensity reflects total HDAC4 protein abundance

• Pattern in Western blots: Can detect both phosphorylated and unphosphorylated forms of HDAC4, often appearing as multiple bands

Comparative advantages in specific research scenarios:

For comprehensive analysis of HDAC4 regulation, researchers often benefit from using both antibody types in parallel experiments to distinguish between changes in protein levels and post-translational modifications.

How can researchers investigate the functional relationship between ATM and HDAC4 using phospho-specific antibodies?

To investigate the functional relationship between ATM and HDAC4 using phospho-specific antibodies, researchers can implement a multi-faceted experimental approach:

Establishing the ATM-PP2A-HDAC4 signaling axis:

• Co-immunoprecipitation studies:

  • Immunoprecipitate PP2A-A from wild-type and ATM-deficient samples

  • Probe with phospho-[S/T]Q antibodies (recognizing the ATM/ATR target sites) to confirm ATM-dependent phosphorylation of PP2A-A at S401

  • Immunoprecipitate HDAC4 and probe for PP2A-A and PP2A-C to assess their association in wild-type vs. ATM-deficient conditions

• Phosphorylation site mapping:

  • Perform in vitro kinase assays with purified ATM and PP2A-A (wild-type and S401A mutant) to confirm direct phosphorylation

  • Use phospho-Ser632 HDAC4 antibodies to monitor changes in HDAC4 phosphorylation state in response to ATM modulation

Manipulating the pathway with genetic and pharmacological approaches:

• ATM inhibition experiments:

  • Treat cells with ATM inhibitors (caffeine 2mM or KU55933 10μM)

  • Monitor HDAC4 localization and phosphorylation state at different time points (e.g., 1, 3, 6 hours)

  • Quantify nuclear accumulation of HDAC4 and reduction in phospho-Ser632 signal

• PP2A modulation:

  • Pretreat cells with PP2A inhibitor (endothall) before ATM inhibition

  • Use shRNA against PP2A subunits (PR65 and PP2CA) in ATM-deficient models

  • Assess whether blocking PP2A activity prevents nuclear accumulation of HDAC4

• Rescue experiments:

  • Express phosphomimetic (S632D) HDAC4 in ATM-deficient cells

  • Assess whether this prevents nuclear accumulation and downstream effects

Downstream functional analysis:

• Chromatin binding and gene regulation:

  • Perform ChIP-seq with HDAC4 antibodies in wild-type vs. ATM-deficient conditions

  • Validate binding sites with ChIP-qPCR using primers designed within identified peaks

  • Correlate binding patterns with changes in histone acetylation and gene expression

• Sensitivity to DNA damage:

  • Expose wild-type and ATM-deficient neurons to low doses of DNA-damaging agents (e.g., etoposide)

  • Modulate HDAC4 levels/activity using shRNA or overexpression

  • Assess neuronal survival and apoptotic markers (e.g., activated caspase-3)

Proposed experimental scheme for comprehensive analysis:

This comprehensive approach will provide mechanistic insights into how ATM regulates HDAC4 through PP2A and the functional consequences of this regulation in neuronal homeostasis and response to DNA damage.

What methodological approaches can elucidate the differential regulation of class IIa HDACs (HDAC4, HDAC5, HDAC7) in ATM-deficient conditions?

To investigate the differential regulation of class IIa HDACs in ATM-deficient conditions, researchers should employ a systematic approach that addresses the specificity observed in HDAC4 nuclear accumulation compared to HDAC5 and HDAC9:

Comparative subcellular localization analysis:

• Immunofluorescence co-staining:

  • Perform simultaneous immunofluorescence for HDAC4, HDAC5, and HDAC9 in wild-type and ATM-deficient tissues/cells

  • Quantify nuclear/cytoplasmic ratios for each HDAC using digital image analysis

  • This approach has revealed that HDAC4, but not HDAC5 or HDAC9, shows significant nuclear accumulation in ATM-deficient Purkinje cells

• Subcellular fractionation:

  • Prepare nuclear and cytoplasmic fractions from wild-type and ATM-deficient samples

  • Analyze by Western blotting using antibodies against each HDAC

  • Include phospho-specific antibodies (e.g., phospho-Ser632 for HDAC4, phospho-Ser661 for HDAC5, phospho-Ser486 for HDAC7)

Phosphorylation status assessment:

• Comparative phosphorylation analysis:

  • Immunoprecipitate each class IIa HDAC from wild-type and ATM-deficient samples

  • Analyze phosphorylation status using:
    a. Phospho-specific antibodies for conserved regulatory sites
    b. Phospho-serine/threonine antibodies
    c. Mass spectrometry-based phosphoproteomics

• 14-3-3 binding assays:

  • Perform co-immunoprecipitation of each HDAC with 14-3-3 proteins

  • Compare binding efficiency between wild-type and ATM-deficient conditions

  • This revealed reduced association between HDAC4 and 14-3-3 in ATM-deficient conditions

Phosphatase interaction studies:

• PP2A association analysis:

  • Immunoprecipitate each class IIa HDAC and probe for PP2A subunits

  • Alternatively, immunoprecipitate PP2A-A or PP2A-C and probe for each HDAC

  • Compare association patterns between wild-type and ATM-deficient conditions

  • Research has shown increased HDAC4-PP2A association in ATM-deficient samples

• Phosphatase inhibition experiments:

  • Treat ATM-deficient cells with phosphatase inhibitors (e.g., endothall for PP2A)

  • Monitor localization of each HDAC to determine if inhibition differentially affects their distribution

Domain-specific regulation investigation:

• Chimeric protein experiments:

  • Create chimeric proteins by swapping domains between HDAC4 and HDAC5/9

  • Express these chimeras in ATM-deficient cells

  • Determine which domains confer sensitivity to ATM-dependent regulation

• Site-directed mutagenesis:

  • Introduce mutations at key regulatory phosphorylation sites

  • Compare the effect on subcellular localization in ATM-deficient conditions

  • Focus on sites that differ between HDAC4 and other class IIa HDACs

Functional transcriptional analysis:

• ChIP-seq comparative binding:

  • Perform ChIP-seq for each class IIa HDAC in wild-type and ATM-deficient conditions

  • Compare binding patterns to identify unique and shared target genes

  • Research has shown distinct chromatin binding patterns for HDAC4 in ATM-deficient conditions

• Transcription factor interaction:

  • Assess interaction with known partners (MEF2, CREB) for each HDAC

  • Determine if ATM deficiency differentially affects these interactions

Proposed experimental matrix:

This comprehensive approach will help elucidate why HDAC4 is specifically affected by ATM deficiency while other closely related class IIa HDACs remain largely unaffected.

How can researchers validate the specificity and phospho-sensitivity of HDAC4 (Ab-632) Antibody in their experimental systems?

To rigorously validate both the specificity and phospho-sensitivity of HDAC4 (Ab-632) Antibody, researchers should implement a comprehensive validation strategy incorporating multiple complementary approaches:

1. Genetic validation strategies:

• HDAC4 knockdown/knockout controls:

  • Transfect cells with HDAC4-specific siRNA or shRNA constructs

  • Generate HDAC4 knockout cell lines using CRISPR-Cas9

  • Compare antibody signal between control and HDAC4-depleted samples

  • A specific antibody should show significantly reduced or absent signal in knockdown/knockout samples

• Overexpression controls:

  • Transfect cells with GFP-tagged or Flag-tagged HDAC4 constructs

  • Compare detection between endogenous and overexpressed protein

  • Co-localization of antibody signal with tag signal in immunofluorescence provides strong validation

  • Research has shown that GFP-HDAC4 shows similar localization patterns to endogenous HDAC4 in response to ATM deficiency

2. Phosphorylation-specific validation:

• Phosphatase treatment:

  • Treat cell lysates or nuclear extracts with calf intestinal alkaline phosphatase (CIP)

  • Compare treated and untreated samples by Western blot

  • For phospho-Ser632 antibodies, signal should be significantly reduced or eliminated

  • For total HDAC4 antibodies, band pattern should shift to faster-migrating forms

• Phospho-mimetic and phospho-deficient mutants:

  • Generate S632A (cannot be phosphorylated) and S632D/E (phospho-mimetic) HDAC4 mutants

  • Express in cells and analyze with both phospho-specific and total antibodies

  • Phospho-specific antibodies should not detect S632A but may detect S632D/E

  • Total antibodies should detect all variants with possible mobility shifts

3. Pharmacological manipulations:

• Kinase and phosphatase inhibition:

  • Treat cells with agents that alter HDAC4 phosphorylation:

    • ATM inhibitors (caffeine 2mM, KU55933 10μM)

    • PP2A inhibitors (endothall)

    • PKA inhibitors (H89)

    • CaMK inhibitors

  • Monitor changes in antibody signal intensity and pattern

  • These treatments should produce predictable changes in phospho-specific antibody reactivity

4. Peptide competition assays:

• Immunizing peptide competition:

  • Pre-incubate antibody with excess phosphorylated or non-phosphorylated peptide (A-Q-S-S-P)

  • Apply to parallel Western blots or immunofluorescence samples

  • Specific signal should be blocked by the appropriate competing peptide

  • For phospho-specific antibodies, only phospho-peptide should compete effectively

5. Cross-reactivity assessment:

• Related protein analysis:

  • Test antibody against recombinant HDAC5 and HDAC9

  • Compare signal in cells overexpressing different HDAC family members

  • A specific antibody should show minimal cross-reactivity with related proteins

6. Technical validation controls:

• Reproducibility between detection methods:

  • Compare results between Western blotting and immunofluorescence

  • Verify that subcellular distribution patterns are consistent across methods

  • Confirm that treatments affect antibody reactivity similarly across techniques

• Multiple antibody validation:

  • Use multiple antibodies targeting different HDAC4 regions

  • Compare results with commercial phospho-Ser632 antibodies from different vendors

  • Consistent results across antibodies increases confidence in specificity

Comprehensive validation experimental matrix: